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Abstract
Purpose Administration of positively charged amino acids
has been introduced to reduce the nephrotoxicity of targeted
radiopeptide therapy (TRT). However, the amino acid
solution may have side effects, including hyperkalaemia.
The aim of this study was to evaluate the frequency and the
magnitude of hyperkalaemia in neuroendocrine tumour
(NET) patients undergoing TRT.
Methods Enrolled in the study were 31 patients with NET
eligible for TRT with [90Y-DOTA(0),Tyr(3)]octreotide (90Y-
DOTATOC). Their mean age was 54±14 years. Of these 31
patients, 21 (67%) were referred for the first treatment cycle,
while 10 (33%) were referred for a subsequent therapy cycle.
Patients were treated with therapeutic doses of 90Y-DOTA-
TOC ranging from 7,030 to 35,520 MBq. To inhibit tubular
reabsorption of 90Y-DOTATOC, 1 l of physiological saline
solution containing 25 g of arginine hydrochloride and 25 g
of lysine hydrochloride was given over 4 h starting 1 h
before 90Y-DOTATOC injection. All patients underwent a
standard biochemical blood analysis at baseline, and 4 h and
24 h after the beginning of the amino acid infusion.
Results ANOVA repeated measures showed a significant
overall effect on K+ levels over time (F=118.2, df=2, P<
0.0001). Mean serum levels of K+ were 4.00±0.33 mmol/
l at baseline, 5.47±0.57 mmol/l at 4 h, and 4.38±
0.63 mmol/l at 24 h after the beginning of the infusion.
Post-hoc analysis showed that K+ levels at 4 h were
significantly (P<0.05) higher than at baseline. K+ levels at
24 h were significantly (P<0.05) lower than at 4 h but they
were still significantly (P<0.05) higher than K+ levels at
baseline. On a subject-by-subject basis, none of the 31
patients had increased K+ levels at baseline. At 4 h, 24 of
the 31 patients (77%) had K+ levels above the normal
range, and 6 patients (19%) experienced severe hyper-
kalaemia (K+ ≥ 6 mmol/l). All patients with increased K+
levels were clinically asymptomatic. At 24 h, only 4
patients (13%) had increased K+ serum levels. The
magnitude of the increase in K+ levels between baseline
and 4 h was relatively homogeneous over the whole group
(1.41 ± 0.50 mmol/l) and it was not related (linear
regression, P>0.05) to baseline K+ levels. Intravenous
administration of 40 mg furosemide 1 h after the beginning
of the amino acid infusion did not have a significant effect
on K+ levels (P>0.05). No clinical characteristic was
predictive for the increase in K+ levels (chi-squared test,
P > 0.05).
Conclusion Hyperkalaemia is a frequent, potentially life-
threatening side effect of basic amino acid infusion during
TRT. K+ levels 4 h after the beginning of the infusion
should be monitored in patients at risk of complications,
such as those with heart disease and those with risk factors
for nephrotoxicity.
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Introduction
Targeted radiopeptide therapy (TRT) is an effective thera-
peutic approach for patients with neuroendocrine tumour
(NET) who are no longer eligible for surgery [1]. This
therapy relies on the use of radiolabelled peptides that
preferentially bind to the somatostatin receptor 2 (SST2).
Following binding, the peptide–receptor complex is rapidly
internalized, and the radioactive peptide is trapped in the
cell and produces cytotoxic damage [2].
Bone marrow toxicity and kidney toxicity are
generally dose-limiting factors of TRT [3–6]. Renal
uptake of radiolabelled somatostatin (SST) analogues
occurs in the proximal tubule cells and largely depends
on the multiligand megalin/cubulin system [7]. The
receptor involved in the renal uptake of radioactive
peptides binds various structurally different proteins,
including albumin and β2 microglobulin [8]. Basic amino
acids, including arginine and lysine, bind to megalin via
their cationic sites and therefore competitively inhibit
renal reabsorption of radioactive peptide used in TRT [8–
13]. The reduction in renal uptake induced by cationic
amino acids ranges between 15% and 60% depending on
the amount of amino acids being used and on the
experimental design [9–13]. However, amino acid sol-
utions may have some disadvantages. For examples, they
can induce nausea and vomiting, hyperosmolarity and
hyperkalaemia, and at high doses they may themselves
induce nephrotoxicity [12, 14]. Among these side effects,
hyperkalaemia may be particularly dangerous because it
is associated with a high risk of cardiac arrhythmias [15–
17]. This is particularly true in patients with preexisting
heart disease. The aim of this prospective study was to
assess the effect of amino acid solutions on serum
potassium (K+) concentrations in patients with NET




The study included 31 patients with NET eligible for TRT.
Their mean age was 54±14 years. The clinical character-
istics of the patients are summarized in Table 1. Disease
was confirmed in all patients by histology. Overexpression
of SST2 was documented prior to TRT by [
111In-DTPA0]
octreotide scintigraphy or PET/CT using 68Ga-labelled SST
analogues. In all patients the use of long acting SST
analogues had been withdrawn for at least 6 weeks prior to
TRT and short-acting SST analogues had been withdrawn
for at least 3 days prior to TRT.
Exclusion criteria were: (a) pregnancy or lactation; (b)
age <21 years; (c) Karnofsky performance status <60 and
life expectancy <6 months; (d) white blood cell count <2×
109/l; (e) haemoglobin <80 g/l; (f) platelets <100×109/l,
and (g) increased creatinine levels. Written informed
consent was obtained from all patients. The study was
approved by the local ethics committee.
Radiopharmaceuticals
90Y-DOTATOC was synthesized in-house according to a
previously published procedure [18, 19]. 90Y was pur-
chased from Perkin Elmer (USA) and 111In was purchased
from Tyco Healthcare (Petten, The Netherlands). The final
radiopharmaceutical was analysed by thin-layer chroma-
tography (Biodex) using a phosphor imager (Cyclone
Plus, Perkin Elmer) and reverse-phase high-performance
liquid chromatography (Bischoff) using a Chromolith
column (Merck) and a γ-detector (Berthold) [19]. The
radiolabelling yield and radiochemical purity of 90Y- and
111In-DOTATOC were higher than 99.5%.
TRT
Patients were hospitalized for 3 days in accordance with the
legal requirements for radioactivity protection. Of the 31
patients included, 21 (67%) were referred for the first
treatment cycle, and 10 (33%) were referred for a
subsequent therapy cycle.
To inhibit tubular reabsorption of 90Y-DOTATOC, 1 l
of physiological solution containing 25 g of arginine
hydrochloride and 25 g of lysine hydrochloride was given
1 h before TRT. The infusion pump was set to 250 ml/
h starting 1 h before 90Y-DOTATOC injection for a total
infusion time of 4 h. In each therapy session, 111 MBq of
111In-DOTATOC was coinjected with 90Y-DOTATOC to
allow scintigraphic imaging. The therapeutic cumulative
radioactivity doses ranged from 7,030 to 35,520 MBq of
90Y–DOTATOC. All patients were symptomatic or had
progressive disease. The following risk factors for the
development of kidney toxicity were identified: arterial
hypertension, diabetes, renal morphological abnormalities,
history of use of radiological contrast medium and history
of chemotherapy with nephrotoxic agents [4].
Measurement of K+ levels and blood radioactivity
All patients underwent a standard baseline haematological
and biochemical analysis of blood. The biochemical
analysis was repeated 4 h and 24 h after the beginning of
the amino acid infusion. No tourniquet was applied while
drawing blood samples to avoid potential bias in the
measurement of K+ levels. Since the primary aim of this
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study was to assess the effect of amino acid solution on K+
levels, the haematological evaluation was not repeated after
TRT. Additionally, we assessed the feasibility of preventing
the amino acid-induced increase in K+ serum levels in 19
patients who underwent a subsequent TRT after 10–
12 weeks. For this aim, we administered 40 mg furosemide
i.v. 5 min before the second 90Y–DOTATOC injection. The
dose of furosemide was chosen on the basis of a previous
study in humans indicating that kaliuresis following i.v.
injection of 40 mg furosemide peaks 30 min after the
injection and returns to baseline by 3.5 h [20].
Blood samples (4–5 ml) were collected into lithium
heparin gel tubes (S-Monovette). Within 30 min of blood
withdrawal, all blood samples were centrifuged at
3,000 rpm (1,830 g; Multicentrifuge 3SR+, Thermo
Scientific) for 5 min in the C-laboratories of the Nuclear
Medicine Department. After centrifugation, the baseline
sample was directly sent to the central hospital laboratory
for biochemical and haematological analysis. K+ levels
were measured by potentiometric determination using an
ion-selective electrode (ISE 900, Modular; Roche). Normal
K+ values ranged from 3.7 to 4.7 mmol/l (Table 1). Samples
of serum (400 μl) were used for K+ measurements (test
volume 65 μl). Other analytes were measured according to
standard methods.
The radioactive samples taken at 4 h and 24 h after the
beginning of the infusion were stored for 48 h in a
refrigerator at 4°C to allow for radioactivity decay. This
procedure became necessary because we had a priori no
information on whether the activity levels in blood samples
were within safety limits for handling outside the C-
laboratories of the Nuclear Medicine Department. Accord-
Table 1 Clinical characteristics of the patients
Patient no. Sex Age (years) Primary tumour Documented lesions Previous therapies
1 F 61 Small-bowel NET Liver, lymph nodes SST analogues, transarterial chemoembolization
2 F 46 Paraganglioma Liver, lymph nodes, bone Surgery, SST analogues
3 F 59 NET of unknown origin Liver, lymph nodes SST analogues
4 F 60 NET of unknown origin Liver, bone SST analogues
5 M 61 Pancreatic NET Liver, bone Surgery
6 F 36 NET of unknown origin Liver, bone SST analogues, chemotherapy
7 F 45 Pancreatic NET Liver SST analogues
8 M 26 NET of unknown origin Liver, bone SST analogues, chemotherapy
9 F 38 Pancreatic NET Liver SST analogues
10 F 77 Pancreatic NET Liver, bone Surgery
11 F 18 Pancreatic NET Liver SST analogues
12 F 52 Meningioma Local relapse Gamma knife
13 M 39 Small-bowel NET Liver, lymph nodes SST analogues
14 F 52 Lung carcinoid Local relapse Surgery
15 F 57 Paraganglioma Local relapse None
16 F 68 NET of unknown origin Liver SST analogues
17 M 58 Rectal NET Liver, lymph nodes Surgery, transarterial chemoembolization
18 M 50 Pancreatic NET Liver SST analogues
19 F 51 Pancreatic NET Liver SST analogues
20 M 50 Pancreatic NET Liver bone SST analogues
21 M 65 Pancreatic NET Liver SST analogues, chemotherapy
22 F 72 Pancreatic NET Liver, lymph nodes Surgery, SST analogues
23 F 60 Pancreatic NET Liver, bone SST analogues
24 F 41 Pancreatic NET Liver None
25 M 80 NET of unknown origin Liver None
26 M 57 Pancreatic NET Liver Surgery, SST analogues, chemotherapy
27 F 68 Pancreatic NET Liver, bone Chemotherapy
28 M 59 Small-bowel NET Liver, lymph node Surgery
29 F 54 Pancreatic NET Liver SST analogues, chemotherapy, interferon
30 F 51 Gastric NET Liver Surgery, SST analogues
31 M 56 Lung carcinoid Liver, lymph node Surgery, SST analogues
Eur J Nucl Med Mol Imaging (2011) 38:1675–1682 1677
ing to the recommendations of the International Commis-
sion on Radiological Protection (ICRP) [21] the hand dose
limit for non-occupationally exposed persons, as it applies
to the personnel of the central hospital laboratory, is
50 mSv/year. The Swiss authorization limit for 90Y under
which radioactive blood samples can be processed in
nonspecialized laboratories is 3 MBq.
Dose-rate (microsieverts per hour) measurements of
whole-blood samples (4–5 ml) obtained 4 h and 24 h
after the beginning of the infusion were determined
directly in the sample tube with a dose-rate detector
(Berthold LB 133/LB 6006). The amount of radioactivity
(megabecquerels) was measured in 50 μl of the serum
which was mixed with 10 ml scintillation liquid (Ultima
Gold, Perkin Elmer) and analysed in duplicate in a β-
counter (1500 Tri-Carb, Packard). To extrapolate the
level of radioactivity in the samples at 4 h and 24 h after
the beginning of the infusion, the measured values were
corrected for radioactive decay and scaled to a volume of
400 μl. After verification that neither a C-laboratory was
required nor the hand dose limit had been exceeded, the
4-h and 24-h blood samples were also sent to the central
hospital laboratory for biochemical analysis.
Statistics
Differences between K+ levels at baseline, and 4 h and 24 h
after the beginning of the infusion of the amino acid
solution were assessed by ANOVA repeated measures
using K+ serum levels as repeated factor. Post-hoc tests
were performed with Student"s t-test. The relationship
between the number of patients developing hyperkalaemia
and clinical characteristics of the study group was evaluated
with the chi-squared test. Statistical significance was set at
P<0.05.
Results
ANOVA repeated measures showed a significant overall
effect on K+ levels over time (F=118.2, df=2, P<
0.0001). Mean serum levels of K+ were 4.00 ±
0.33 mmol/l at baseline, 5.47±0.57 mmol/l at 4 h, and
4.38±0.63 mmol/L at 24 h. Post-hoc analysis showed that
K+ levels at 4 h were significantly (P<0.05) higher than at
baseline. K+ levels at 24 h were significantly lower than at
4 h, but they were still significantly higher than K+ levels
at baseline (Fig. 1).
On a subject-by-subject basis, none of the 31 patients
had increased K+ levels at baseline. At 4 h, 24 of the 31
patients (77%) had K+ levels above the normal range, and 6
(19%) showed several hyperkalaemia (K+ ≥ 6 mmol/l). The
highest K+ level was 6.7 mmol/l. At 24 h, only 4 patients
(13%) had K+ serum levels above the normal range. No
patient reported palpitations.
The magnitude of the increase in K+ serum levels
between baseline and 4 h was relatively homogeneous in
the whole group (1.41±0.50 mmol/l) and it was not related
to baseline K+ levels (P>0.05; Fig. 2).
The numbers of patients who developed hyperkalaemia
did not differ between those undergoing the first therapy
cycle and those undergoing subsequent therapy cycles
(90% and 71% of patients, respectively; P=0.25), between
those who received less and those who received more than
the median dose of 12,950 MBq (71% and 86% of patients,
respectively; P=0.29), between those with and those
without clinical risk factors for nephrotoxicity (83% and
Fig. 2 Increase in K+ serum levels at 4 h after the beginning of the
infusion in relation to the baseline K+ serum levels. The equation of
the line is: Y=−0.279X+2.59, r2=0.03; P=0.35
Fig. 1 Serum K+ concentrations (millimoles per litre) at baseline, and
at 4 h and 24 h after the beginning of the infusion of the amino acid
solution (4-hours post-infusion, 24-hours post-infusion). *P<0.05 in
comparison to baseline; #P < 0.05 in comparison to 24-hours
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74% of patients, respectively; P=0.43), or between those
younger and those older than the median age (56 years;
81% and 73% of patients, respectively; P=0.68).
In 19 patients who had K+ measurements after
furosemide injection, K+ serum levels 4 h after the
beginning of the infusion were significantly higher than
baseline (5.17±0.74 vs. 3.88±0.45 mmol/l; P<0.05).
There was no significant (P>0.05, paired t-test) difference
between the 4-h K+ value after furosemide injection and
the corresponding 4-h value (5.36±0.41 mmol/L) without
furosemide administration. Serum K+ levels 24 h after the
beginning of the infusion (4.18±0.41 mmol/l) were still
significantly (P<0.05) higher than at baseline. On a
subject-by-subject basis 13 of the 19 patients (68%)
experienced hyperkalaemia 4 h after the beginning of the
infusion. This value was not significantly different (P>
0.05, chi-squared test) from the percentage of patients who
experienced hyperkalaemia in the absence of furosemide
administration.
Radioactivity levels in the volume of serum required for
K+ analysis (400 μl) were 13.3–79.0 kBq (mean value
38.0 kBq) and 0.5–10.8 kBq (mean value 3.3 kBq) in
samples obtained at 4 h and 24 h after the beginning of the
infusion, respectively (n=15). These values correspond to
about 10% and 1% of the injected dose at 4 h and 24 h,
respectively, and are in good agreement with previously
reported data on the excretion rate of 90Y-DOTATOC [19].
Measurement of whole blood (4–5 ml; n=10) at 4 h gave a
dose-rate of 140–400 μSv/h (mean value 248 μSv/h). The
effects of the amino acid infusion on other biochemical
variables are summarized in Table 2.
Discussion
Under normal conditions 95% of K+ is found within the
cells, while the remaining 5% is in the blood. This
concentration gradient is maintained by the Na+/K+ ATPase
pump and is regulated by endocrine as well as non-
endocrine factors [22]. The kidney is responsible for
maintaining normal K+ balance. The renal elimination of
K+ is passive (through the glomerulus), and reabsorption is
active in the proximal tubule and the ascending limb of the
loop of Henle. There is active excretion of potassium in the
distal tubule and the collecting duct; both are controlled by
aldosterone. Of the usual dietary intake of K+, 90% is
excreted by the kidney, and the remaining 10% is excreted
in the stool [23].
Several drugs may induce hyperkalaemia. Three mech-
anisms can be distinguished: (1) increased K+ input (i.e.
potassium chloride supplements); (2) decreased K+ output
(i.e. K+-sparing diuretics); (3) induction of a shift of K+
from cells to the extracellular compartment. Arginine
monohydrochloride and lysine monohydrochloride induce
hyperkalaemia according to the third mechanism [10, 12,
24, 25]. The ability to drive K+ out of the cell is a property
of all cationic amino acids, and has been demonstrated in
vitro [24] and in vivo [25]. The shift of K+ from cells to the
extracellular compartment is proportional to the serum
levels of the amino acid. In turn, this shift increases renal
K+ excretion [25]. This may explain the fact that the
increase in K+ concentration after amino acid infusion
during TRT is typically transient (Fig. 1).
The increase in K+ levels after amino acid infusion was
relatively homogeneous in the whole group and it was not
related to baseline K+ levels. Increased K+ levels were
detected in 77% of patients in our study group, and 19% of
patients had severe hyperkalaemia. These results are
unexpectedly high, given that the changes in K+ concen-
tration induced by amino acid solution have been generally
considered mild [10, 12, 26]. Rolleman et al. assessed the
effect of different preparations of amino acid solutions on
kidney radioactivity uptake as well as on K+ levels. Serum
K+ levels significantly increased from 4.2±0.5 to 5.1±
0.6 mmol/l after administration of 25 mg lysine and 25 mg
arginine [12]. The percentage of patients with increased K+
levels was not reported. Barone et al. studied the effect of
different amino acid solutions on a variety of chemical
parameters [10]. They found increased K+ serum levels in
patients treated with 50 g lysine, as well as in patients
Normal range Baseline 4 h 24 h
K+ (mmol/l) 3.7–4.7 4.00±0.33 5.47±0.57*# 4.38±0.63*
Na+ (mmol/l) 131–142 138.8±3.3 134.9±5* 138.6±2.6
Cl− (mmol/l) 97–110 101.5±3.8 107.7±6.6*# 103.6±3.2*
Phosphate (mmol/l) 0.80–1.50 1.04±0.20 0.76±0.24*# 1.20±0.21*
Urea (mmol/l) 3.0–7.8 5.7±2.2 7.7±2.3*# 7.2±2.3*
Creatinine (μmol/l) 45–93 65.4±26.1 67.2±20.7 64.4±16.5
Uric acid (μmol/l) 173–359 301.2±87.7 259.0±80.3*# 272.9±70.4*
Lactate dehydrogenase (U/l) 135–214 234.3±111.5 217.4±110.7* 227.5±123.2
Creatine kinase (U/l) 38–157 103.2±67.9 74.5±37.3 68.8±53.1
Table 2 Biochemical results at
baseline, and at 4 h and 24 h
after the beginning of the amino
acid infusion. Values are means
±SD.
*P<0.05 compared to baseline;
#P<0.05 compared to 24-hours.
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treated with 25 g lysine and 25 g arginine. K+ levels after
amino acid infusion (5.1 mmol/l in both groups) were lower
than in our study. Interestingly, no increase in K+ levels was
found in patients treated with a mixture of amino acids [10].
Jamar et al. assessed the effects of five amino acid
regimens, including a prolonged 10-h infusion with 240 g
amino acids that included 52.8 g lysine and arginine [33].
They found that, in comparison to the standard 4-
h protocol, the protective effect on the kidneys according
to dosimetry data was enhanced by the prolonged infusion.
The effect on K+ levels was, however, not reported.
Several factors may explain the higher levels of K+ that
we detected in comparison to those reported by Barone et
al. [10] and Rolleman et al. [12] when using similar
amounts of amino acid, and include the rate of infusion, the
timing of blood sampling and the characteristics of the
study group. Barone et al. assessed K+ levels 2.5 h after the
start of the infusion. The initial infusion rate was higher
than the final infusion rate although values were not
provided. On the basis of Fig. 1, it is reasonable to expect
that the change in K+ levels after peptide receptor
radionuclide therapy has an initial ascending phase fol-
lowed by a slower descending phase. Depending on the
timing of the peak, early blood withdrawal, such as at 2.5 h,
might lead to underestimation of K+ levels. Higher infusion
rates will probably increase the slope of the ascending
phase of the curve with an effect on K+ levels depending on
the timing of blood sampling. The timing of blood
withdrawal as well as the rate of infusion was not specified
in the study by Rolleman et al. [12]. Note, however, that
Rolleman et al. reported an increase in K+ levels from 4.4±
0.5 to 5.9±0.8 mmol/l after infusion with 75 mg lysine.
This value, that is greater than the value we reported,
underlines the primary importance of amino acid amounts
on K+ levels. Finally, we cannot exclude the possibility that
differences in K+ susceptibility may have been related to
the clinical characteristics of the patients.
Another explanation for our findings relates to the
potential occurrence of spurious hyperkalaemia [27]. This
occurs when blood cells release intracellular K+ as a
consequence of haemolysis. Haemolysis may take place if
too much pressure is applied during blood withdrawal or if
processing of the blood sample is delayed. To avoid
haemolysis in our study a tourniquet was not applied while
drawing blood samples. Moreover, all blood samples were
centrifuged within 30 min of blood withdrawal. Ultimately,
the occurrence of haemolysis after peptide receptor radio-
nuclide therapy was definitively excluded by the lack of an
increase in lactate dehydrogenase levels at 4 h as well as at
24 hours after the beginning of infusion (Table 2).
Patients with congestive heart failure (CHF) may have
disturbances in K+ homeostasis. Decreased K+ excretion
may occur as a result of reduced glomerular filtration rate,
which is quite common in CHF [23, 28, 29]. Reduced K+
excretion is also a side effect of drugs used for the therapy
of CHF, namely angiotensin-converting inhibitors,
angiotensin-receptor blockers and aldosterone receptor
antagonists such as spironolactone, and other potassium-
sparing diuretic agents [23, 28–30]. Hyperkalaemia may
induce an impairment in cardiac conduction which can
result in ventricular fibrillation or asystole [15, 31, 32].
Typical electrocardiogram (ECG) findings in hyperkalae-
mia include flattened P waves, prolonged PR interval, wide
QRS and tall peaked T waves [15]. No significant changes
in ECG were reported by Jamar et al. and Barone et al. in
the patients experiencing hyperkalaemia [10, 33]. For this
reason, ECG was not routinely performed in our study.
However, fatal cardiac arrhythmias induced by hyper-
kalaemia may also occur in clinically silent patients [17].
For these reasons, K+ levels should be monitored in patients
with CHF or in patients prone to cardiac arrhythmias.
Another group of patients in whom K+ levels should be
monitored carefully is those with NET with clinical risk
factors for the development of kidney toxicity undergoing
TRT. Patients with hypertension, diabetes, renal morpho-
logical abnormalities, history of use of radiological contrast
medium and history of chemotherapy with nephrotoxic
agents are more likely to develop nephrotoxicity following
TRT [4]. In diabetic patients, the combined deficiency of
insulinism and aldosterone, which respectively enhance
cellular K+ uptake and promote K+ elimination, is frequent-
ly complicated by hyperkalaemia [23, 34]. Other risk
factors independently associated with an increased likeli-
hood of hyperkalaemia include reduced glomerular filtra-
tion rate, advanced age, increased creatinine levels and
increased urea nitrogen level [23, 29, 30].
In a selected group of patients scheduled for two
consecutive TRT sessions, K+ levels were also determined
after furosemide injection during the second therapy cycle.
Furosemide is a potent loop diuretic that increases renal
excretion of K+ by inhibiting the Na+-K+-Cl− symporter
and is used for the acute therapy of hyperkalaemia [35].
The kaliuresis of 40 mg furosemide injected i.v. peaks
30 min after injection and returns to baseline by 3.5 h [20].
Therefore, we investigated whether furosemide would be
effective in preventing or limiting the increase in K+ serum
levels induced by the amino acid infusion. However, the
percentage of patients who developed hyperkalaemia was
very similar in the two conditions (77% vs. 68%). The lack
of effect of furosemide is probably explained by the fact
that the peak concentration of the drug occurs relatively
early. Therefore, furosemide only moderately counteracts
the effect of amino acid solution occurring after the early
part of the infusion. This contrasts with the setting of acute
hyperkalaemia where K+ values are already at the peak
when furosemide is injected. These results indicate that i.v.
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injection of furosemide as performed in this study is not
useful for preventing hyperkalaemia in patients with NET
undergoing TRT.
There are other potential approaches to reducing neph-
rotoxicity. Polypeptide-based succinylated gelatin, plasma
expander Gelofusine (Braun) and Haemaccel (Hoechst)
have been shown to induce low molecular weight protein-
uria by reducing the tubular reabsorption process [36, 37].
Plasma expanders also reduce the renal uptake of diagnostic
doses of [111In-DTPA0]octreotide efficiently in animals and
in healthy volunteers without showing the typical side
effects of amino acid infusion [36, 37]. In rats albumin
fragments have been shown to reduce renal uptake of
[111In-DTPA0]octreotide as efficiently as lysine [38].
However, the benefit of plasma expanders and albumin
fragments in patients during TRT remains to be assessed.
However, our results indicate that these alternatives should
be carefully investigated and followed further in order to
avoid potentially life-threatening side effects of the amino
acid infusion.
Measurement of K+ concentrations during TRT has the
logistical difficulty of handling radioactive materials. This
can be of concern for laboratories that do not regularly
handle radioactive materials and have no full access to
radiation protection equipment, for example, the central
hospital laboratory where the described biochemical and
haematological analysis of blood samples were carried out.
Our investigations show that the radioactivity levels in all
serum samples used for K+ analysis (maximum 79 kBq in
400 μl) are below the threshold (3 MBq) which requires
special facilities, and for most samples taken 24 h after the
beginning of the infusion, below the exemption limit
(4 kBq). In any case, proper handling and disposal of the
blood samples is required at all times. The average time
needed for sample preparation and to carry out K+
measurements is approximately 15 min in total. Based on
the determined dose-rates (maximum 0.4 mSv/h), it can be
concluded that the radiation burden to laboratory personnel
which results from the handling of a whole blood sample
(e.g. in the case of a medical emergency) is not of concern
and neither is the total amount of radioactivity handled
(≤1 MBq/ per ml; see above). It is important to note that
Swiss regulations do not apply to other countries and
domestic laws and regulations must be followed.
Amino acid solution has been reported to induce grade I
and grade II gastrointestinal toxicity in 10% to 69% of
patients depending on the type of solution and pattern of
infusion [10, 11]. This effect can be attributed to a pressure
decrease in the lower oesophageal sphincter induced by
amino acids [10, 39]. In the current study, mild and
transient gastrointestinal toxicity was also detected in about
one-third of patients. However, some patients experienced
nausea or vomiting within 2–3 min after 90Y-DOTATOC
injection. Thus, it is possible that both radiopeptide
injection as well as amino acid solution may induce mild
gastrointestinal symptoms in patients with NET treated with
TRT. Similarly, muscle weakness and fatigue, two symp-
toms that may be related to hyperkalaemia, are frequently
reported in patients treated with TRT. Numbness of the
lips [40] was reported by one patient with K+ levels of
5.4 mmol/l. The effects of amino acid solution on other
chemical compounds deserve some comment. In the
whole group, mean phosphate levels were significantly
reduced 4 h after the beginning of the infusion compared
to baseline. This finding may be attributed to increased
anabolism or decreased reabsorption of phosphorus [10].
Decreased chloride levels may be related to transient
acidosis [10]. We did not observe any increase in
creatinine levels in the whole study group. This finding
is consistent with a previous report [10] and further
confirms that amino acid solution may be used to reduce
nephrotoxicity in patients with NET undergoing TRT [11–
14, 41, 42]. However, there was a slight but significant
increase in urea levels after TRT. This increase can be
attributed to the fact that arginine is the amino acid most
involved in the urea cycle [10].
Conclusions
In summary, transitory hyperkalaemia occurred 4 h after the
beginning of the infusion of basic amino acids in up to 77%
of patients with NET undergoing TRT. Severe hyper-
kalaemia occurred in 19% of patients, and this could be
potentially life threatening with regard to cardiac arrhyth-
mia. Preadministration of furosemide was not effective in
preventing the increase in K+ levels. K+ levels 4 h after the
beginning of the infusion should be monitored in selected
patients, such as those with heart disease and those with
clinical risk factors for nephrotoxicity. Alternative routes to
lower kidney uptake such as plasma expanders should be
further investigated.
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